ELDN Research and Charts

ELDN - Eledon Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 2.09	Change ⇓ -0.04 (-1.88%)	Volume 441,795
	Open 2.14	High 2.17	Low 2.06

8EMA (Daily) 2.13	40EMA (Daily) 2.03	50EMA (Daily) 2.05	STO (Daily) 37.189	MACD Hist (Daily) -0.034
8EMA (Weekly) 2.057	40EMA (Weekly) 2.53	50EMA (Weekly) 2.62	STO (Weekly) 33.853	MACD Hist (Weekly) 0.094


Company Profile
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.